StreetInsider.com News Articles

Cadrenal Therapeutics CMO resigns, separation terms disclosed

Fri, 17 Jul 2026 16:21:02 -0400

Cadrenal Therapeutics (NASDAQ: CVKD) has entered into a separation agreement with James J. Ferguson III, its Chief Medical Officer, following his resignation announced July 7, 2026.

According to a company statement, Dr. Ferguson notified the board of his decision to resign effective July 31, 2026. The separation agreement, dated July 9, 2026, was formally entered into on July 14, 2026.

Under the terms of the agreement, Dr. Ferguson will receive his current salary through his last day, reimbursement of approved business expenses, and up to six months of COBRA health insurance premium payments, provided he remains eligible and does not obtain coverage

Cadrenal Therapeutics CMO resigns, separation terms disclosed

Fri, 17 Jul 2026 16:21:02 -0400

Cadrenal Therapeutics (NASDAQ: CVKD) has entered into a separation agreement with James J. Ferguson III, its Chief Medical Officer, following his resignation announced July 7, 2026.

Form 8-K Cadrenal Therapeutics, For: Jul 14

Fri, 17 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260717/26784503.html

Form 8-K Cadrenal Therapeutics, For: Jul 14

Fri, 17 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260717/26784503.html

Form D Cadrenal Therapeutics,

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774841.html

Form D Cadrenal Therapeutics,

Wed, 15 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26774841.html

Cadrenal Therapeutics (CVKD) files for 2.94M share offering by sellign stockholders

Mon, 13 Jul 2026 17:14:17 -0400

Cadrenal Therapeutics (NASDAQ: CVKD) has filed for up to 2,942,400 share offering by selling stockholders.

Cadrenal Therapeutics (CVKD) files for 2.94M share offering by sellign stockholders

Mon, 13 Jul 2026 17:14:17 -0400

Cadrenal Therapeutics (NASDAQ: CVKD) has filed for up to 2,942,400 share offering by selling stockholders.

Form S-3 Cadrenal Therapeutics,

Mon, 13 Jul 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260713/26763195.html

Form S-3 Cadrenal Therapeutics,

Mon, 13 Jul 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260713/26763195.html

Cadrenal phase 2 data show 25% drop in clotting events for HIT drug

Mon, 13 Jul 2026 09:01:33 -0400

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) reported phase 2 clinical data for its investigational drug CAD-1005 at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, showing a reduction of more than 25% in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT).

The data were presented in a late-breaking oral session by principal investigator Dr. Steven E. McKenzie. The trial is described as the first randomized, blinded, placebo-controlled study conducted in HIT patients. Patients treated with CAD-1005 experienced new or worsening thrombotic events at a rate of approximately 50%, compared with more than 75% in the placebo arm. The

Cadrenal phase 2 data show 25% drop in clotting events for HIT drug

Mon, 13 Jul 2026 09:01:33 -0400

Cadrenal phase 2 data show 25% drop in clotting events for HIT drug

Mon, 13 Jul 2026 09:01:33 -0400

Cadrenal phase 2 data show 25% drop in clotting events for HIT drug

Mon, 13 Jul 2026 09:01:33 -0400

Cadrenal phase 2 data show 25% drop in clotting events for HIT drug

Mon, 13 Jul 2026 09:01:33 -0400

Cadrenal phase 2 data show 25% drop in clotting events for HIT drug

Mon, 13 Jul 2026 09:01:33 -0400

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress